JSH‐23 targets nuclear factor‐kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: Nuclear factor‐kappa B (NF‐ κ B) being reported to play an important role in the pathogenesis of diabetic neuropathy is believed to be a central mechanism involved in the genesis and promulgation of inflammatory insult. Here we have targeted the nuclear translocation of NF‐ κ B using JSH‐23 to elucidate its role in diabetic neuropathy. Methods: JSH‐23 (1 and 3 mg/kg) was administered for 2 weeks in diabetic rats, after 6 weeks of diabetes induction using streptozotocin (55 mg/kg) as diabetogenic agent. Functional (motor nerve conduction velocity and blood flow), behavioural (mechanical hyperalgesia), biochemical [malondialdehyde, glutathione, tumour necrosis factor‐ α (TNF‐ α ) and interleukin‐6 (IL‐6) levels] and NF‐ κ B translocation studies (western blot technique) were then undertaken. Results: JSH‐23 treatment significantly reversed the nerve conduction and nerve blood flow deficits seen in diabetic animals. Reduction in mechanical pain threshold was also partially corrected by the treatment. Protein expression studies showed that nuclear translocation of p65/p50 subunit was inhibited by JSH‐23 treatment in the sciatic nerve. The treatment also lowered the elevated IL‐6, TNF‐ α , cyclo‐oxygenase (COX‐2) and inducible nitric oxide synthase (iNOS) levels/expression, indicating reduction in the inflammatory damage of the sciatic nerve. Apart from these effects, JSH‐23 also increased Nrf2 and hemeoxygenase‐1 (HO‐1) levels which could imply its potential in increasing the strength of antioxidant defence. Conclusion: We observed that NF‐ κ B inhibition partially reversed functional, behavioural and biochemical deficits with JSH‐23 treatment. This study substantiates the role of NF‐ κ B activation in the aetiology of diabetic neuropathy and protection afforded by inhibition of NF‐ κ B by JSH‐23, which can be attributed to its effect on neuroinflammation and oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, G.-H., Qu, J., & Shen, X. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.002 · Cited by 697 · cited 1×
“Nrf2 and NF-κB cross each other at various interfaces affecting each other’s activities [51].”
BackgroundWhen NRF2 Talks, Who's Listening?
Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S., & Kensler, T. W. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3216 · Cited by 595 · cited 1×
“This can result in hindrance in the transcription of various proteins playing crucial role in body’s antioxidant defence [52].”
BackgroundNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · cited 1×
“NF-κB is one of the primary transcription factors initiating inflammatory response and contributing to exaggeration of inflammatory damage [33].”
BackgroundMedeiros, R., Prediger, R. D. S., Passos, G. F., Pandolfo, P., Duarte, F. S., Franco, J. L., Dafre, A. L., Di Giunta, G., Figueiredo, C. P., Takahashi, R. N., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5047-06.2007 · Cited by 292
Shin, H.-M., Kim, M.-H., Kim, B. H., Jung, S.-H., Kim, Y. S., Park, H. J., Hong, J. T., Min, K. R., & Kim, Y. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.056 · Cited by 269
Cited by
Sandireddy, R., Yerra, V. G., Areti, A., Komirishetty, P., & Kumar, A. (2014) · International Journal of Endocrinology · doi:10.1155/2014/674987 · Cited by 364
Self-citationMolecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Susceptibility to Innate Immune Activation in Genetically Mediated Myocarditis
Selgrade, D. F., Fullenkamp, D. E., Chychula, I. A., Li, B., Dellefave-Castillo, L., Dubash, A. D., Ohiri, J., Monroe, T. O., Blancard, M., Tomar, G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180254 · Cited by 30
“We also tested JSH-23, an inhibitor of NF-κ B transcriptional activity (46).”
MethodChen, D., Sui, L., Chen, C., Liu, S., Sun, X., & Guan, J. (2022) · Aging · doi:10.18632/aging.203824 · Cited by 29
Metadata
- Authors
- Kumar, A., Negi, G., & Sharma, S. S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-06-21
- Volume
- 13
- Issue
- 8
- Pages
- 750-758
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1999344705
- Cited by
- 118
- References
- 5
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JSH‐23 targets nuclear factor‐kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01402.x
- The paper
- Kumar, A., Negi, G., & Sharma, S. S. (2011). JSH‐23 targets nuclear factor‐kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01402.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.